



Interim Report
January - June 2025

Acarix Second Quarter & First Half 2025 Summary

KEY Q2 TAKEAWAYS

Second quarter 2025 compared to the same period in 2024

- Total revenue amounted to SEK 1,140 thousand (1,958), a decrease of 42%, as expected based on divesting in the EU and focus efforts in the US and that the majority of CADScor units were consigned vs sold
- Currency adjusted revenue decreased by 37%
- In the US, revenue amounted to SEK 595 thousand (1,040) a decrease by 43% (all consigned CADScor Units)
- Currency adjusted revenue decreased by 37% in the U.S.
- A total of 19 CADScor Systems (15) were delivered, an increase of 27%. All 19 systems were consigned and installed at customer sites within the US market.
- A total of 2,780 patches (3,530) were sold, reflecting a 21% decrease (lower EU Sales as expected)
- In the U.S., patch sales amounted 1,400 (1,260), an increase of 11%
- Gross margin amounted to 94% (91)
- Operating costs amounted to SEK 13,915 thousand (18,368), a decrease of 24%
- Net loss was SEK -12,863 thousand (-16,661), an improvement of 23%
- Net cash flow for the period was SEK -13,027 thousand (-15,242)
- Earnings per share were SEK -0.01 (-0.02).

First half of 2025 compared to the same period in 2024

- Total revenue amounted to SEK 2,870 thousand (3,509), a decrease of 18%
- Currency adjusted revenue decreased by 17%
- In the US, revenue amounted to SEK 1,829 thousand (2,008), a decrease of 9%
- Currency adjusted revenue decreased by 7% in the U.S.
- A total of 39 CADScor Systems (28) were delivered, an increase of 39%
- In the U.S., 38 CADScor Systems (27) were delivered, an increase of 41%
- A total of 5,940 patches (6,054) were sold, a decrease of 2%
- In the U.S., 3,520 patches (2,300) were sold, an increase of 53%
- Gross margin amounted to 86% (91)
- Operating costs amounted to SEK 29,352 thousand (34,708), a decrease of 15%
- Net loss amounted to SEK -26,971 thousand (-31,591)
- Net cash flow amounted to SEK -24,794 thousand (12,742)
- Cash and cash equivalents amounted to SEK 32,260 thousand (48,271)
- Earnings per share amounted to SEK -0.02 (-0.04)
- A number of shares amounted to 1,123,320,142 (1,123,320,142).

Significant Events during the Quarter

April

- N/A

May

- Aamir Mahmood, President and CEO of Acarix, announced an increase in his investment in the company by acquiring 1,000,000 shares at an average price of SEK 0.20. Following this acquisition, he holds a total of 9,904,824 shares and 50,000,000 stock options.

June


- Acarix announced that the first payor has agreed to provide fixed reimbursement for the CADScor® System at a rate of \$300. The payor is a regional Third Party Administrator (TPA) based in Oklahoma, specializing in the administration of self-funded employee benefit plans.
- Acarix announced the publication of a new peer-reviewed study in PharmacoEconomics – Open demonstrating that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments. Results showed that a “CADScor-First” strategy could lead to substantial cost savings—estimated between \$7.3 million and \$15.3 million per 10,000 patients—without compromising patient safety.

Significant events after June 30, 2025

- Acarix announced its first order in the Middle East and North Africa (MENA) region. Valued at 1.35M SEK, this order from a leading regional distributor represents a significant step in Acarix’s international expansion strategy.
- Acarix announced that a second payer has agreed to provide fixed reimbursement of \$300 for the CADScor® System. This reimbursement applies across both physician office settings and outpatient/emergency department (ED) environments. This Payer provides a Network that services employers and individuals in the Oklahoma, Texas, Ohio, and Louisiana markets which consists of over 500,000 covered lives with 12,000+ Primary Care Physicians, 69,000+ Specialists and 3,000+ Facilities/Ancillaries.


U.S. Acoustic Patch Sales

Accumulated



U.S. CADScor System Installations

Accumulated



Comments from the CEO

In Q2, we continued to execute on our strategy to focus resources on the U.S. market, positioning Acarix for long-term, sustainable growth. This strategic shift inevitably meant a temporary slowdown in Germany, as expected, until we have the resources to fully re-engage that market. Our priority remains clear: establish a strong U.S. foothold, secure reimbursement, and drive adoption of the CADScor® System as a first-line diagnostic tool for chest pain.

While the path to fixed reimbursement in the U.S. has taken longer than anticipated, the progress made in Q2 marks a turning point. In June, we secured our first fixed-rate reimbursement from a U.S. payor at \$300 per test. Shortly after quarter close, a second payor came on board, expanding coverage to more than 500,000 lives across multiple states. This second agreement proves that the first was not an isolated win, and we believe it signals the start of a snowball effect that will unlock broader access for providers and accelerate adoption. Historically, the evolution to fixed reimbursement takes 12–18 months, and we are closing in on the 12-month mark with the largest payor in the U.S.

Commercial performance in the U.S. was strong. We delivered 19 CADScor® Systems, a 36% increase over Q2 last year, while patch sales rose 11%. This validates a core belief: once the CADScor® System is installed, clinicians use it consistently. This is the best proof point we can ask for, showing not only installation growth but also deep clinical integration.

Our financial discipline remains a competitive strength during the quarter. We maintained a 94% gross margin, reduced operating expenses by 24%, and improved net loss by 23% year-over-year. These results demonstrate that our operating model is scalable and that we are advancing with purpose while preserving efficiency.

Our value proposition is also being reinforced by strong peer-reviewed evidence. A recent publication in *PharmacoEconomics – Open* demonstrated that the CADScor® System could reduce healthcare costs by \$7.3M to \$15.3M per 10,000 U.S. emergency department patients. Applied at scale, this represents a multi-billion-dollar potential savings opportunity for the healthcare system, a compelling case for payors, hospital systems, and providers alike.

I remain deeply confident in our mission and market opportunity. In Q2, I personally increased my equity position by acquiring an additional 1 million shares, underscoring my commitment to Acarix and my belief in our trajectory.

As we move into the second half of the year, our focus is clear:

- Expand reimbursement coverage across key regional payors
- Drive clinical utilization through targeted provider engagement
- Scale U.S. commercial operations while maintaining operational efficiency
- Elevate market awareness of the CADScor® System as the standard of care for chest pain triage

Our vision is unchanged: to make CADScor® Systems the standard of care in chest pain triage, and to do so with economic, clinical, and human impact at the center of everything we build, and we are very optimistic in our ability to achieve these goals.

To our investors, our partners, and our team: thank you for your continued support and belief.

Aamir Mahmood
President & CEO

Financial Reports

Profit/Loss Statements

Second quarter

During the current quarter, net sales amounted to SEK 1,140 thousand, compared to SEK 1,958 thousand in the corresponding period of the previous year, representing a decline of 42%. Adjusted for currency changes, sales declined by 37%. The decline in sales is primarily due to an expected decrease in patch sales within the DACH region, based on the divestment in that area. Additionally, sales were impacted by a one-time, strategically priced order from a key U.S. customer to promote higher patch utilization in the future.

In terms of system deliveries, a total of 19 systems were shipped as consignments during the quarter, all within the U.S. market. In the same quarter of the prior year, 15 systems were delivered, of which 13 were consignments and one was sold directly in the U.S. market.

In the U.S., patch sales experienced an increase, rising from 1,260 units to 1,400 units, reflecting an 11% growth compared to the same quarter in 2024. The slower growth rate for patch sales in the U.S. is due to large patch orders received in previous quarters, which decreased the need for additional purchases this quarter. Additionally, the lead time for system installation and training during the period impacts patch sales in the short term.

The gross margin on patch sales remained strong at 94%, maintaining a 3 percentage point improvement over the same quarter of the previous year.

Operating expenses for the period totaled SEK -13,915 thousand, representing a 24% decrease compared to SEK 18,368 thousand in the same period of 2024. This reduction underscores the company's ongoing cost-saving initiatives and improved operational efficiency, which are now fully realized.

The net loss for the period amounted to SEK -12,863 thousand, representing an improvement of SEK 3,798 thousand, or 23%, compared to the same period last year.

First half year

Revenue for the period totaled SEK 2,870 thousand (3,509), with 90% of this amount generated from patch sales. The substantial contribution from patches is primarily due to the adoption of our U.S.-based business model, which involves placing systems on consignment. In the first six months, we delivered 39 systems to the market, of which 19 were on consignment—compared to a total of 28 systems last year, with 23 on consignment. This consignment-based approach positions us for sustainable growth and future expansion.

Gross profit was SEK 2,473 thousand, representing a gross margin of 86%, compared to SEK 3,202 thousand and a 91% margin in the same period of 2024. The 5 percentage point decline is primarily due to two one-time, strategically priced orders in the previous 6 months for key customers, intended to promote future high patch utilization.

Total operating expenses for the period were SEK 29,352 thousand, down from SEK 34,708 thousand in the previous year, reflecting a cost reduction of SEK 5,356 thousand or 15%.

The net loss for the period was SEK -26,971 thousand, representing an improvement of SEK 4,624 thousand, or 15%, compared to the same period last year.

Financial Position Overview

Tangible assets totaled SEK 402 thousand, related to the net assets of CADScor Systems under the consignment model in the U.S. market. Intangible assets comprise the net value of patents and development costs, with a carrying amount of SEK 8,011 thousand (compared to SEK 10,942 thousand as of June 30). No acquisitions were made during the period. The inventory value reached SEK 7,277 thousand, reflecting a 22% increase from SEK 5,980 thousand in the same period last year. This rise in inventory is to accommodate the increased demand in the U.S. market. The company's cash position amounted to SEK 32,260 thousand.

As of June 30, equity amounted to SEK 47,728 thousand, compared to SEK 67,807 thousand as of June 30, 2024. The share capital was SEK 11,233 thousand, with a total of 1,123,320,142 shares registered at Swedish Companies Registration Office.

Total current liabilities were SEK 5,153 thousand, compared to the previous year's SEK 11,811 thousand.

Cash Flow and Financing

Second quarter

Cash flow from operating activities, including changes in working capital, amounted to SEK -12,665 thousand (compared to SEK -15,258 thousand) for the second quarter. The negative cash flow primarily reflects the net loss and negative changes in working capital, driven by increased inventory levels to meet demand for our products. Cash flow from investing activities for the second quarter was SEK -361 thousand (compared to SEK 16 thousand), related to the capitalization of consigned CADScor systems. There was no cash flow from investing activities during the quarter. Net cash flow for the period was SEK -13,027 thousand (-15,242).

First half year

For the period January - June 2025, cash flow from operating activities, including changes in working capital, totaled SEK -24,332 thousand (compared to SEK 33,694 thousand in 2024). The negative cash flow is mainly due to the net loss. Cash flow from investing activities for the first six months was SEK -462 thousand (compared to SEK 162 thousand 2024), related to the capitalization of consigned CADScor systems. Financing activities was SEK 46,598 thousand related to the right issue after deduction of transaction costs. Net cash flow for the first six months was SEK -24,794 thousand (-12,742).

The Parent Company

The Board of Directors and executive management work continuously to secure the company's long-term financing to ensure the operation of the business. The company's growth plan is continuously balanced against the financial resources available at any given time. The established growth plan, which is driven by market demand, might require additional financing during 2025, which can be obtained through, for example, loans or issuances of shares.

Auditor's Review

This interim report has not been reviewed by the company's auditor.

Certified Advisor

Carnegie Investment Bank is the Certified Advisor of Acarix.

Financial Reports

Shareholder Register June 30, 2025

	Number of shares	Votes and capital
Ibkr Financial Services AG	209,603,430	18.7%
Försäkringsaktiebolaget Avanza Pension	39,616,035	3.5%
Life Science Invest Fund 1 Aps	38,677,762	3.4%
Carl Johan Mikael Thoren	34,209,755	3.0%
Cbny-Charles Schwab Fbo Customer	29,245,121	2.6%
Ubp Clients Assets - Sweden	26,228,413	2.3%
Filip Frojden	24,162,504	2.2%
Microtech Software AS	20,513,884	1.8%
Saxo Bank A/s Client Assets	20,374,508	1.8%
LLC Pershing	16,505,324	1.5%
10 largest owners	459,136,736	40.9%
Other owners	664,183,406	59.1%
Total as of June 30, 2025	1,123,320,142	100%

Financial Calendar

Interim Report, Q3 2025 November 6, 2025

Interim Report, Q4 2025 February 12, 2026

For more information, please contact

Christian Lindholm

CFO

Email: christian.lindholm@acarix.com

Group - Consolidated Statement of Income

kSEK	April - June 2025	April - June 2024	January - June 2025	January - June 2024	Year 2024
Revenue	1,140	1,958	2,870	3,509	6,202
Cost of goods sold	-72	-169	-396	-307	-607
Gross profit	1,068	1,788	2,473	3,202	5,595
Research and development costs	-3,985	-5,517	-8,276	-10,343	-25,385
Sales, general and administrative costs	-9,930	-12,851	-21,076	-24,365	-46,583
Operating profit	-12,847	-16,580	-26,879	-31,506	-66,373
Financial income	34	26	88	64	453
Financial costs	-49	-107	-181	-149	-267
Profit before tax	-12,863	-16,661	-26,971	-31,591	-66,187
Tax		-		-	-
Net loss for the period	-12,863	-16,661	-26,971	-31,591	-66,187
Net income attributable to parent company's shareholders	-12,863	-16,661	-26,971	-31,591	-66,187
Basic earnings per share (SEK)	-0.01	-0.02	-0.02	-0.04	-0.07
Diluted earnings per share (SEK)	-0.01	-0.02	-0.02	-0.04	-0.07
Average number of shares, before dilution (thousands)	1,123,744	852,500	1,123,744	813,170	920,813
Average number of shares, after dilution (thousands)	1,123,744	852,500	1,123,744	813,170	920,813

Group - Consolidated Statement of Comprehensive Income

kSEK	April - June 2025	April - June 2024	January - June 2025	January - June 2024	Year 2024
Net loss for the period after tax	-12,863	-16,661	-26,971	-31,591	-66,187
Items that may be reclassified to profit or loss					
Foreign currency translation adjustment	-1,962	-434	-4,124	505	1,105
Other comprehensive income for the period, net of tax	-1,962	-434	-4,124	505	1,105
Total comprehensive income for the period, net of tax	-14,825	-17,095	-31,095	-31,087	-65,082
Total comprehensive income attributable to:					
Owners of Acarix	-14,825	-17,095	-31,095	-31,087	-65,082

Group - Consolidated Statement of Financial Position

kSEK	June 30, 2025	June 30, 2024	Year 2024
Assets			
Tangible assets			
Tangible assets	402	191	470
Total tangible assets	402	191	470
Intangible assets			
Acquired rights	3,345	3,699	3,603
Development projects, capitalized	4,665	7,242	6,080
Total intangible assets	8,011	10,942	9,683
Financial assets			
Long term financial receivable	-	920	-
Total financial assets	-	920	-
Total fixed assets	8,413	12,052	10,153
Current assets			
Inventory	7,277	5,980	7,083
Accounts receivables	1,937	3,421	2,195
Other receivables	2,994	9,894	2,715
Cash and cash equivalents	32,260	48,271	58,615
Total current assets	44,468	67,566	70,608
Total assets	52,881	79,618	80,761
Shareholders's equity and liabilities			
Equity			
Share capital	11,233	9,732	11,233
Other contributed capital	675,272	636,392	675,272
Reserves	3,253	4,614	5,215
Retained earnings	-615,059	-551,341	-549,836
Result for the period	-26,971	-31,591	-66,187
Total equity	47,728	67,807	75,697
Current liabilities			
Accounts payable	1,874	2,472	1,394
Other liabilities	3,279	9,339	3,670
Total current liabilities	5,153	11,811	5,064
Total equity and liabilities	52,881	79,618	80,761

Group - Consolidated Statement of Changes In Equity

kSEK	Share capital	Share premium	Other reserved	Retained earnings & result of the year	Total shareholders equity
As at 1 January 2025	11,233	675,272	5,215	-616,023	75,697
Profit/loss for the period				-26,971	-26,971
Other comprehensive income:					
Foreign exchange rate adjustment			-1962		-1,962
Total	11,233	675,272	3,253	-642,994	46,764
Transactions with owners:					
Issue of warrants				964	964
At June 30, 2025	11,233	675,272	3,253	-642,030	47,728
As at 1 January 2024	7,372	592,153	4,110	-551,750	51,885
Profit/loss for the period				-31,591	-31,591
Other comprehensive income:					
Foreign exchange rate adjustment			505		505
Total	7,372	592,153	4,614	-583,341	20,799
Transactions with owners:					
Issue of warrants				410	410
Share issue	2,360	44,957			47,317
Costs related to share issue		-718			-718
At June 30, 2024	9,732	636,392	4,614	-582,932	67,807

Group - Consolidated Statement of Cash Flow

kSEK	April - June 2025	April - June 2024	January - June 2025	January - June 2024	Year 2024
Operating activities					
Operating result	-12,847	-16,580	-26,879	-31,506	-66,373
Adjustment for depreciation	847	725	1,739	1,436	3,290
Other non-cash items		-		-	878
Financial items	-16	-81	-92	-85	186
Cash-flow before change of working capital	-13,217	-15,936	-25,232	-30,155	-62,019
Working capital adjustments:					
Change in inventory	-834	1,142	-187	1,005	-181
Change in receivables and prepayments	9	-589	494	-2,367	2,060
Change in trade and other payables	175	123	593	-2,179	-3,185
Total change in working capital	-650	677	900	-3,541	-1,306
Cash -flow from operating activities	-12,665	-15,258	-24,332	-33,694	-63,325
Investing activities					
Investment in fixed assets	-361	16	-462	-162	-920
Cash-flow from investing activities	-361	16	-462	-162	-920
Financing activities					
Rights issue after deduction of transaction costs	-	-	-	46,598	86,980
Cash flow from financing activities	-	-	-	46,598	86,980
Cash flow for the period	-13,027	-15,242	-24,794	12,742	22,735
Currency translation differences	239	-412	-1,561	380	731
Cash and cash equivalents, beginning of period	45,048	63,925	58,615	35,149	35,149
Cash and cash equivalents, end of period	32,260	48,271	32,260	48,271	58,615

Parent Company - Income Statement

kSEK	April - June 2025	April - June 2024	January - June 2025	January - June 2024	Year 2024
Other revenues	500	1,000	3,500	2,000	11,231
Sales, general and administrative costs	-1,264	-3,435	-3,348	-6,523	-22,901
Operating result	-764	-2,435	152	-4,523	-11,670
Profit / Loss from shares in group companies	-10,669	-15,475	-27,297	-26,232	-54,302
Financial income	-	30	-	47	334
Financial expense	-	-13	-	-31	-68
Profit before tax	-11,433	-17,894	-27,145	-30,738	-65,706
Tax	-	-	-	-	-
Net loss for the period	-11,433	-17,894	-27,145	-30,738	-65,706
Net income attributable to Parent Company's Shareholder	-11,433	-17,894	-27,145	-30,738	-65,706

Parent Company - Balance Sheet

kSEK	June 30, 2025	June 30, 2024	Year 2024
Assets			
Fixed assets	-	16	-
Total fixed assets	-	16	-
Financial assets			
Participations in subsidiaries	44,868	44,868	44,868
Total financial assets	44,868	44,868	44,868
Current assets			
Other receivables	4,346	3,136	549
Cash and cash equivalents	17,577	38,946	49,655
Total current assets	21,923	42,083	50,204
Total assets	66,791	86,967	95,072
Shareholders' equity and liabilities			
Equity			
Share capital	11,233	9,732	11,233
Other capital contribution	459,167	420,287	459,167
Retained earnings	-406,725	-344,613	-379,580
Total equity	63,675	85,406	90,820
Current liabilities			
Accounts payable	116	349	196
Intercompany payables	1,789	-	2,681
Other liabilities	1,210	1,212	1,375
Total current liabilities	3,115	1,561	4,252
Total equity and liabilities	66,791	86,967	95,072

Parent Company - Consolidated Statement of Change In Equity

kSEK	Share capital	Share premium	Retained earnings & result of the year	Total shareholders equity
As at 1 January 2025	11,233	459,167	-379,580	90,820
Profit/loss for the period			-27,145	-27,145
Total comprehensive income				
At June 30 2025	11,233	459,167	-406,725	63,675
As at 1 January 2024	7,372	376,048	-313,874	69,546
Profit/loss for the period			-30,738	-30,738
Total comprehensive income	7,372	376,048	-344,613	38,807
Transactions with owners:				
Share issue	2,360	44,957	-	47,317
Costs related to share issue		-718	-	-718
Total transactions with owners	2,360	44,239	-	46,599
At June 30 2024	9,732	420,287	-344,613	85,406

Notes

Note 1 Corporate Information

Company Information

Acarix AB (559009-0667) is a limited liability company incorporated and domiciled in Malmö, Sweden. The registered office is located at Regus, Hyllie Boulevard 34, 215 32 Malmö, Sweden. Acarix's main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services.

The Acarix Group Consists of:		
Acarix A/S	The main operating company	Incorporated and located in Denmark
Acarix GmbH	Supporting sales on the German market (under liquidation)	Incorporated and located in Germany, under liquidation
Acarix Inc	Supporting sales on the US market	Incorporated and located in USA
Acarix Ltd	Supporting sales on the UK market	Incorporated and located in UK
Acarix Incentive AB		Incorporated and located in Sweden

Note 2 Basis of Preparation

The interim report for the Group and Parent Company comprises summary consolidated financial statements for Acarix AB (publ). The interim consolidated financial statements include the Company's wholly-owned subsidiaries according to above specification.

Note 3 Accounting Policies

The consolidated report has been prepared in accordance with International Financial Reporting Standards (IFRS) and IAS 34, Interim Financial Reporting. Acarix continues to apply the same accounting principles and valuation methods as those described in the most recent annual report. The Parent Company report is prepared in accordance with RFR 2, Accounting for Legal Entities, the Swedish Annual Accounts Act and accounting principles and the valuation methods as those described in the most recent annual report.

Note 4 Significant Accounting Policies, Judgments and Assumptions

In preparing the interim report, certain provisions under IFRS require management to make judgments, which may significantly impact the group's financial statements. For additional descriptions of significant judgments and estimates, refer to note 4 in the annual report 2024.

Note 5 Risk Management

The Acarix Group is exposed to business and financial risks through its operations. These risks have been described at length in the company's annual report 2024. In addition to the risks described in these documents, no additional significant risks have been identified.

Note 6 Related Parties

Related parties comprise the members of the Board of Directors and other senior executives. Apart from remuneration of the Board of Directors, no transactions with related parties were carried out during the period.

Note 7 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the group and the revenue can be reliably measured, regardless of when the payment is received. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duty. The specific recognition criteria described below must also be met before revenue is recognized.

Sale of goods

Revenue from the sale of goods is recognized when the significant control of ownership of the goods has passed to the buyer, usually on delivery of the goods. Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates.

Revenues from agreements with customers

Sales SEK	2025 Q1	2025 Q2	2025 Q1-Q2
Germany	366	530	896
USA	1,235	595	1,830
Sweden	128	15	143
Total	1,729	1,140	2,870

Revenues from leases with customers

Sales SEK	2024 Q1	2024 Q2	2024 Q1-Q2
Germany	580	789	1369
USA	972	1,032	2004
Sweden	-	87	87
Austria	-	19	19
Other	-	30	30
Total	1,552	1,957	3,509

Affirmations

This interim report has been prepared in accordance with International Accounting Standard (IAS) 34 “Interim Financial Reporting” and in accordance with the Swedish Annual Accounts Act. With respect to the Parent Company, this interim report has been prepared in accordance with the Swedish Annual Accounts Act and in compliance with RFR2, Accounting for Legal Entities. The Board of Directors and the CEO certify that this interim report presents a true and fair overview of the Group’s and the Parent Company’s operations, financial position and results of operations, and describes the significant risks and uncertainties facing the Parent Company and the companies belonging to the group.

August 21, 2025

Executive Management

Aamir Mahmood

President & CEO

Board of Directors

Jan Poulsen

Chairman of the Board

Tony Das

Board Member

Kenneth Nelson

Board Member

Marlou Janssen

Board Member

Leadership

Aamir Mahmood

President & CEO

Christian Lindholm

Chief Financial Officer

Carma Connely

Head of Operations & Customer Excellence

Jeff Thomas

Head of US Sales

Beji George

Head of Global Strategy & Therapy Development

Dwyndi Nelms

Head of QA, RA & Production

Jeffrey Rudd

Head of US Finance

Daniel Burke

Head of Reimbursement & Market Access

Macie May

Head of Marketing & Public Relations



Hyllie Boulevard 34, 5TR

SE- 215 32 Malmö

info@acarix.com

www.acarix.com